206 completed, 74 unknown, 41 recruiting, 32 active not recruiting. 176 Phase 2, 139 Phase 3, 36 Phase 1, 20 Phase 4, 19 Not applicable.
Follow Tamoxifen: new trials by email Literature Review of Tamoxifen trials Research Report on Tamoxifen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 96 | 2026-12-31 | 2026-10-22 |
| A Study of Skipping Radiation Therapy in People With Breast Cancer HER2-targeted therapy, Tamoxifen, No Radiation Therapy - HER2-positive Breast Cancer, Breast Cancer | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 136 | 2026-10-16 | 2026-10-29 |
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| SHORTened Duration of TAMoxifen Tamoxifen, Tamoxifen (Nolvadex) - High Risk for Invasive Breast Cancer | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 250 | 2026-09-01 | 2026-09-08 |
| Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery Adjuvant Radiotherapy, tamoxifen - Ductal Carcinoma In Situ, DCIS | Phase 3 | Recruiting | Fudan University | 636 | 2026-07-01 | 2026-08-13 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Imlunestrant, Goserelin, Tamoxifen 20 mg - Breast Neoplasms | Phase 2 | Recruiting | Eli Lilly and Company | 600 | 2026-05-13 | 2026-10-08 |
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 30 | 2026-03-03 | 2026-04-24 |
| Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Diseases, Breast Neoplasms | Phase 2 | Recruiting | Fujian Cancer Hospital | 2000 | 2026-01-21 | 2026-05-12 |
| Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. Tamoxifen Citrate 20Mg Tab - Cystic Fibrosis - Complete | Phase 2 | Not yet recruiting | Azienda Ospedaliera Universitaria Integrata Verona | 35 | 2026-01-15 | 2025-12-17 |
| Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. Tamoxifen 10 MG, Exemestane 25 MG - Breast Cancer | Phase 2 | Recruiting | Andrea DeCensi | 140 | 2025-10-01 | 2025-11-18 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-11-02 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-08-04 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer Letrozole, Anastrozole, Exemestane - Breast Cancer | Phase 3 | Not yet recruiting | Region Örebro County | 3832 | 2025-05-02 | 2025-04-20 |
| Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas Tamoxifen 20 mg - Pancreatic Neoplasms | Phase 2 | Recruiting | Fudan University | 30 | 2025-03-20 | 2025-04-06 |
Showing 20 of 400. Sign in to see all of them.
Breast Neoplasms (278) · Carcinoma, Intraductal, Noninfiltrating (27) · Breast Carcinoma In Situ (21) · Neoplasm Metastasis (14) · Neoplasms (13) · Breast Neoplasms, Male (12) · Ovarian Neoplasms (10) · Inflammatory Breast Neoplasms (7) · Endometrial Neoplasms (6) · Glioblastoma (6) · Prostatic Neoplasms (6) · Central Nervous System Neoplasms (5) · Brain Neoplasms (4) · Fallopian Tube Neoplasms (4) · Gliosarcoma (4)
National Cancer Institute (NCI) (20) · AstraZeneca (18) · ETOP IBCSG Partners Foundation (8) · Eli Lilly and Company (8) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (7) · Dana-Farber Cancer Institute (6) · Pfizer (6) · Scottish Cancer Therapy Network (6) · University of California, San Francisco (6) · Institut Claudius Regaud (5) · NSABP Foundation Inc (5) · Novartis Pharmaceuticals (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Fred Hutchinson Cancer Center (4) · Fudan University (4)
United States (183) · United Kingdom (46) · Canada (44) · France (43) · Italy (39) · China (37) · Germany (30) · Spain (26) · Belgium (23) · Australia (22) · Brazil (19) · Netherlands (19) · South Korea (18) · Argentina (17) · Taiwan (17)
Raimund Jakesz, MD (4) · Edward F. McClay, MD (3) · W.D. George, MD, MS, FRCS (3) · Antonio Llombart, MD (2) · Barbara L. Smith, MD, PhD (2) · Brenda W. Cooper, MD (2) · Clifford A. Hudis, MD (2) · Daniel Rea, MD (2)
PMID 21247627, PMID 24091623, PMID 24881463, PMID 29885375, PMID 35100692, PMID 41642493, PMID 15632378, PMID 25495490, PMID 26092816, PMID 26276354, PMID 27044936, PMID 27557300, PMID 28732650, PMID 28911092, PMID 29863451, PMID 31618131, PMID 36521078, PMID 36791166, PMID 38979716, PMID 39621968, PMID 40017004, PMID 40633461, PMID 40986647, PMID 41637791, PMID 41980703, PMID 10076721, PMID 10076722, PMID 10210538, PMID 10458221, PMID 10663329, PMID 11228933, PMID 11972444, PMID 12243915, PMID 12490681, PMID 12516764, PMID 12610186, PMID 12798184, PMID 12804433, PMID 14559892, PMID 14652237, PMID 14659350, PMID 14760111, PMID 15014181, PMID 15100340, PMID 15501952, PMID 15685451, PMID 15709195, PMID 15837982, PMID 15837984, PMID 15894097
2023 (5), U10CA032102 (5), 2005 (4), 2016 (4), P30CA043703 (4), 2014 (3), P30CA060553 (3), U10CA180821 (3), U10CA180868 (3), UG1CA242632 (3), 2004 (2), 2009 (2), P30CA033572 (2), P30CA046592 (2), U10CA021115 (2)